973 reports of this reaction
1.9% of all GUSELKUMAB reports
#10 most reported adverse reaction
DEVICE DEPLOYMENT ISSUE is the #10 most commonly reported adverse reaction for GUSELKUMAB, manufactured by Janssen Biotech, Inc.. There are 973 FDA adverse event reports linking GUSELKUMAB to DEVICE DEPLOYMENT ISSUE. This represents approximately 1.9% of all 50,420 adverse event reports for this drug.
Patients taking GUSELKUMAB who experience device deployment issue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
DEVICE DEPLOYMENT ISSUE is a less commonly reported adverse event for GUSELKUMAB, but still significant enough to appear in the safety profile.
In addition to device deployment issue, the following adverse reactions have been reported for GUSELKUMAB:
The following drugs have also been linked to device deployment issue in FDA adverse event reports:
DEVICE DEPLOYMENT ISSUE has been reported as an adverse event in 973 FDA reports for GUSELKUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
DEVICE DEPLOYMENT ISSUE accounts for approximately 1.9% of all adverse event reports for GUSELKUMAB, making it a notable side effect.
If you experience device deployment issue while taking GUSELKUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.